Showing results (871-880 of 891) with videos related to

Sort By:
Pageof 90
NPJ Biofilms and Microbiomes|January 28, 2022
Atherosclerosis amelioration by allicin in raw garlic through gut microbiota and trimethylamine-N-oxide modulationSuraphan Panyod, Wei-Kai Wu, Pei-Chen Chen, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2023
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trialsMei-Jyh Chen, Po-Yueh Chen, Yu-Jen Fang, et al.
Gut|September 5, 2015
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trialJyh-Ming Liou, Chieh-Chang Chen, Chi-Yang Chang, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2018
14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trialJyh-Ming Liou, Chieh-Chang Chen, Yu-Jen Fang, et al.
Therapeutic Advances in Gastroenterology|August 22, 2020
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trialChieh-Chang Chen, Jiing-Chyuan Luo, Yu-Jen Fang, et al.
Nature Aging|July 27, 2026
Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older womenNeil Carleton, Alexander Chih-Chieh Chang, Sanghoon Lee, et al.
The Lancet. Gastroenterology & Hepatology|December 22, 2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trialJyh-Ming Liou, Xiao-Tao Jiang, Chieh-Chang Chen, et al.
Lancet (London, England)|October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
Helicobacter|September 22, 2025
Overall and Stratified Accuracies of H. pylori Serology Testing: A Multicenter Study of 8497 Screening-Naïve AdultsMei-Jyh Chen, Yu-Jen Fang, Chien-Chuan Chen, et al.
Gut|October 2, 2020
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensusJyh-Ming Liou, Peter Malfertheiner, Yi-Chia Lee, et al.
Pageof 90